Combioxin SA
Revolution in the treatment of severe infections
Revolution in the treatment of severe infections
Combioxin SA is a Swiss-based biotech company founded in 2015, with a focus on developing innovative anti-virulence drugs to treat severe bacterial infections and combat antibiotics resistance. The company's slogan - "Revolution in the treatment of severe infections" - underscores its commitment to transforming the approach to infection treatment. In May 2019, it received a Non Equity Assistance investment from MassChallenge, indicating a growing interest in its groundbreaking work. As Combioxin SA continues to advance as a clinical-stage player in the healthcare industry, its unique approach positions it as a promising prospect for venture capital investment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
15 May 2019 |
| Debt Financing | Fr.100.00K | 1 | Foundation for Technological Innovation (FIT) | 14 Oct 2016 |
We care about your data, and we'd love to use cookies make your experience better.
